AstraZeneca (NASDAQ: AZN) announced on Tuesday that its COVID-19 vaccine, Vaxzevria (ChAdOx1-S [Recombinant]) has been given full Marketing Authorisation (MA) in the European Union (EU). Vaxzevria was originally granted a conditional Marketing Authorisation (cMA) by the EU. AstraZeneca stated, "As there continues to be sufficient evidence of safety and efficacy confirming the benefits of Vaxzevria, the European Medicines Agency (EMA) has now granted a full MA." Iskra Reic, EVP, Vaccines and Immune Therapies, AstraZeneca commented, "The move from conditional to full marketing authorisation for Vaxzevria is an important confirmation by the EMA of the safety and efficacy of Vaxzevria, demonstrating that the benefits continue to outweigh the potential risks.
https://www.tipranks.com/news/astrazenecas-covid-19-vaccine-granted-full-approval-in-eu?utm_source=advfn.com&utm_medium=referral
AstraZeneca (NYSE:AZN)
Historical Stock Chart
Von Jan 2023 bis Feb 2023 Click Here for more AstraZeneca Charts.
AstraZeneca (NYSE:AZN)
Historical Stock Chart
Von Feb 2022 bis Feb 2023 Click Here for more AstraZeneca Charts.